NYHETER

2018 9 jul 13:00 First North
Intervacc AB : Intervacc signs an agreement for future filling and release of Strangvac.
Strangvac is Intervacc''s vaccine against strangles, which is a very severe and
contagious infection in the horse. Intervacc has previously signed an agreement
with 3P Biopharmaceuticals in Pamplona, Spain for large-scale commercial
production of the components in Strangvac. The now signed agreement with Praxis
Pharmaceuticals in Spain means that they will provide final formulation, filling
of vials and packaging and final release of finished product.

"With this agreement, we have been assured that the entire manufacturing chain
is in place for commercial production of Strangvac. We look forward to
performing testfilling of vials in the autumn which, among other things, is part
of the work in the ongoing process of transfer of manufacturing technology.
Moreover, the work is proceeding according to a set schedule for the final
production of the validation batches required for the registration application
scheduled to be submitted by the end of 2019", says Jan-Ingmar Flock, CEO of
Intervacc.

For more information please contact:
Jan-Ingmar Flock, CEO
E-mail: jan-ingmar.flock@intervacc.com
Phone: +46-8-120 10 602 or +46-73-334 14 11

The information was submitted for publication, through the agency of the contact
person set out above, at 13:00 CET on July 9, 2018.

About Praxis Pharmaceutical

Praxis Pharmaceutical is a European CDMO specialized in Drug Delivery,
Formulation and ASEPTIC FILL FINISH, including LYOPHILIZATION of Biologics
(proteins, Abs, etc.) and small molecules for clinical manufacturing and
small/medium scale commercial manufacturing. Their brand new aseptic filling
line can be considered as one of the best choices for small/medium size batches
based on its superior process safety and flexibility, especially appropriate for
high value products. http://www.grupo-praxis.com/es/

About 3P Biopharmaceuticals

3P Biopharmaceuticals is a leading CDMO specialized in the process development
and GMP manufacturing of biologics and cell therapy products. Its extensive
experience in projects covering all stages of the process development and GMP
manufacturing in different expression systems, its flexibility and adaptation as
well as innovative technology and its qualified team have made it a reference
for the international biotech market. 3P has the support of an important group
of investors: Cinfa Group. Cinfa Group is a holding of companies that handle
different business lines in the world of health, with more than 50 years of
experience in the biotech and pharma market. It''s flagship company, Laboratorios
Cinfa, is a successful manufacturer that ranks first in terms of generic
dispensed in Spanish retail pharmacies. More info:  http://www.3pbio.com/

About Intervacc

Intervacc AB (publ) is a company within the Biotechnology sector. The Company´s
main area is to develop modern sub-unit vaccines against economically important
bacterial infections, mainly within animal health. The company´s vaccine
candidates are based on several years of research at Karolinska Institute and
Swedish University of Agricultural Research where the foundation was laid for
the company´s research and development work. The Intervacc share has been listed
on the NASDAQ First North market since April 2017 with Eminova Fondkommission AB
as Certified Adviser.

Nyhetsbrev